Azelnidipine

• CAT Number: A000447
• CAS Number: 123524-52-7
• Molecular Formula: C33H34N4O6
• Molecular Weight: 582.7
• Purity: ≥95%
• Target: Calcium Channel
• Solubility: >27.15mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
• InChIKey: ZKFQEACEUNWPMT-UHFFFAOYSA-N
• SMILES: CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C

Azelnidipine, also known as CS 905 and CCRIS 8650, is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate.

Reference

1: Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T.
Azelnidipine is a useful medication for the treatment of heart failure preserved
ejection fraction. Clin Exp Hypertens. 2017;39(4):350-354. doi:
10.1080/10641963.2016.1267198. Epub 2017 May 17. PubMed PMID: 28513286.

2: Jiang D, Kawagoe Y, Kuwasako K, Kitamura K, Kato J. Inhibitory effects of
losartan and azelnidipine on augmentation of blood pressure variability induced
by angiotensin II in rats. Eur J Pharmacol. 2017 Jul 5;806:91-95. doi:
10.1016/j.ejphar.2017.04.018. Epub 2017 Apr 15. PubMed PMID: 28419822.

3: Pan Y, Pang W, Lv J, Wang J, Yang C, Guo W. Solid state characterization of
azelnidipine-oxalic acid co-crystal and co-amorphous complexes: The effect of
different azelnidipine polymorphs. J Pharm Biomed Anal. 2017 May 10;138:302-315.
doi: 10.1016/j.jpba.2017.02.005. Epub 2017 Feb 4. PubMed PMID: 28237872.

4: Ushigome E, Matsumoto S, Oyabu C, Ushigome H, Yokota I, Hasegawa G, Nakamura
N, Tanaka M, Yamazaki M, Fukui M. Olmesartan with azelnidipine versus with
trichlormethiazide on home blood pressure variability in patients with type II
diabetes mellitus. J Am Soc Hypertens. 2017 Mar;11(3):140-147. doi:
10.1016/j.jash.2016.12.004. Epub 2016 Dec 22. PubMed PMID: 28089902.

5: Koike Y, Kawabe T, Nishihara K, Iwane N, Hano T. Effects of azelnidipine and
amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in
hypertensive patients. Hypertens Res. 2016 Dec;39(12):863-867. doi:
10.1038/hr.2016.94. Epub 2016 Jul 21. PubMed PMID: 27439493.

6: Susa N, Nishida Y, Yada Y, Nakayama T, Asai S, Takahashi Y. Comparative effect
of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus
olmesartan medoxomil/azelnidipine on laboratory parameters in patients with
hypertension: a retrospective cohort study. Clin Exp Hypertens. 2016;38(2):173-9.
doi: 10.3109/10641963.2015.1081214. Epub 2015 Oct 9. PubMed PMID: 26453437.

7: Tawaramoto K, Kaneto H, Hashiramoto M, Kawasaki F, Tatsumi F, Shimoda M, Kamei
S, Matsuki M, Mune T, Kaku K. Azelnidipine, but not amlodipine, reduces urinary
albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes:
blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2
study). Diabetol Metab Syndr. 2015 Sep 17;7:80. doi: 10.1186/s13098-015-0073-9.
eCollection 2015. PubMed PMID: 26388951; PubMed Central PMCID: PMC4574138.

8: Tatsumi F, Kaneto H, Hashiramoto M, Tawaramoto K, Obata A, Kimura T, Shimoda
M, Hamamoto S, Kanda-Kimura Y, Kamei S, Mune T, Matsuda M, Kaku K.
Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake
against oxidative stress in 3T3-L1 adipocytes. Endocr J. 2015;62(8):741-7. doi:
10.1507/endocrj.EJ15-0273. Epub 2015 Jul 13. PubMed PMID: 26073866.

9: Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y. Comparison
of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with
Hypertension: The COAT Randomized Controlled Trial. PLoS One. 2015 May
4;10(5):e0125519. doi: 10.1371/journal.pone.0125519. eCollection 2015. PubMed
PMID: 25938807; PubMed Central PMCID: PMC4418830.

10: Patel JK, Patel NK. Validated Stability-Indicating RP-HPLC Method for the
Simultaneous Determination of Azelnidipine and Olmesartan in Their Combined
Dosage Form. Sci Pharm. 2014 Feb 27;82(3):541-54. doi: 10.3797/scipharm.1312-14.
Print 2014 Jul-Sep. PubMed PMID: 25853066; PubMed Central PMCID: PMC4318177.